Skip to Content

C1-Esterase Inhibitor (Human) Injection

Last Updated: January 31, 2018
Status: Current

C1-Esterase Inhibitor (Human) Injection

Products Affected - Description
  • All presentations are currently available

Reason for the Shortage
    • CSL Behring has Berinert available.
    • Shire has resumed manufacturing and Cinryze is available.
    • The subcutaneous dosage form of C1-esterase inhibitor (human) is unaffected by this shortage.
Available Products
  • Berinert intravenous injection, CSL Behring
    500 unit, preservative-free vial (NDC 63833-0825-02)

Cinryze intravenous injection, Shire
500 unit, preservative-free vial (NDC 42227-0081-05)

Estimated Resupply Dates

    • CSL Behring is shipping limited supplies of Berinert to specialty distributers.
    • Shire has certain lots of Cinryze available.

Implications for Patient Care

  • The following lots require filtering prior to administering: 17F19L37OA, 17F24L370A, 17G10L370A, 17G16L370A, 17G21L370A, 17H12L370A, 17G26L370A and 17H22L370A. Additional information and self-administration instructions are available.


January 31, 2018; November 29, October 11 and 4, September 13, August 16, 2017, University of Utah, Drug Information Service. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.